Last update 01 Nov 2024
Shanghai Maiji Biotechnology Co., Ltd.
Last update 01 Nov 2024
Overview
Basic Info
Introduction Shanghai Maiji Biotechnology Co., Ltd. is a leading biotechnology company specializing in the research, development, production, and sales of high-quality bio-products. With a strong focus on innovation and technology, Maiji Biotechnology continuously invests in R&D and strives to stay at the forefront of the biotechnology industry. Founded in 2004 and headquartered in Shanghai, China, Maiji Biotechnology has offices and production facilities in multiple locations worldwide. |
Tags
Respiratory Diseases
Immune System Diseases
Skin and Musculoskeletal Diseases
Monoclonal antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
MG-K10人源化单抗注射液在12-18周岁青少年中重度特应性皮炎患者的确安全性、药代动力学及初步有效性的Ib/IIa期临床研究。
[Translation] A Phase Ib/IIa clinical study to investigate the safety, pharmacokinetics and preliminary efficacy of MG-K10 humanized monoclonal antibody injection in adolescents aged 12-18 years with moderate to severe atopic dermatitis.
Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Effectiveness and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis
MG-K10人源化单抗注射液在中重度特应性皮炎患者中的有效性和安全性的随机、双盲、安慰剂对照III期临床研究
[Translation] A randomized, double-blind, placebo-controlled phase III clinical study on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis
100 Clinical Results associated with Shanghai Maiji Biotechnology Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Shanghai Maiji Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Maiji Biotechnology Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 23 Dec 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
4
Preclinical
Phase 1 Clinical
3
1
Phase 3 Clinical
Other
3
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free